peptide receptor radionuclide therapy + lanreotide

Peptide receptor radionuclide therapy + lanreotide is a combination regimen consisting of peptide receptor radionuclide therapy (PRRT), a form of targeted radiopharmaceutical therapy based on radiolabeled somatostatin analogues, co-administered with lanreotide, a synthetic somatostatin analogue. PRRT involves systemically delivering a somatostatin receptor-targeting peptide (such as DOTA-conjugated lanreotide, octreotide, or octreotate) labeled with a beta-emitting radionuclide (most commonly lutetium-177 or yttrium-90). The radiolabeled peptide binds to overexpressed somatostatin receptors on tumor cells (notably in neuroendocrine tumors), facilitating receptor-mediated internalization and delivering cytotoxic radiation specifically to receptor-expressing tumor cells. Lanreotide is a long-acting synthetic somatostatin receptor agonist that suppresses multiple hormones, slows tumor growth in neuroendocrine tumors, and contributes symptom management. When combined, PRRT provides targeted cell kill by radiation, while lanreotide augments antitumor effects through sustained somatostatin receptor agonism and may provide additional symptom control. This combination is primarily used in unresectable or metastatic neuroendocrine tumors expressing somatostatin receptors, particularly when disease progresses on somatostatin analog therapy alone or as part of multidisciplinary management.